# Pulmonale hypertensie bij MitraClip: COAPT-analyse

*geplaatst 2020-12-01 · Hartfalen · Journal of the American College of Cardiology · doi 10.1016/j.jacc.2020.09.609 · https://hartvaat.nl/2020/12/01/pulmonale-hypertensie-bij-mitraclip-coapt-analyse/*

COAPT analyse naar de impact van pulmonale hypertensie op uitkomsten na MitraClip bij secundaire MR.

## English: Pulmonary Hypertension in Transcatheter Mitral Valve Repair for Secondary Mitral Regurgitation: The COAPT Trial.

This COAPT analysis showed that pulmonary hypertension worsens prognosis in heart failure with secondary MR, but that MitraClip provides consistent benefit regardless of baseline pulmonary pressures.

## Abstract (original, from the publication)

BACKGROUND: Pulmonary hypertension worsens prognosis in patients with heart failure (HF) and secondary mitral regurgitation (SMR). OBJECTIVES: This study sought to determine whether baseline pulmonary hypertension influences outcomes of transcatheter mitral valve repair (TMVr) in patients with HF with SMR. METHODS: In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial, 614 patients with HF with moderate-to-severe or severe SMR were randomized to TMVr with the MitraClip plus guideline-directed medical therapy (GDMT) (n = 302) versus GDMT alone (n = 312). Baseline pulmonary artery systolic pressure (PASP) estimated from echocardiography was categorized as substantially increased (≥50 mm Hg) versus not substantially increased (<50 mm Hg). RESULTS: Among 528 patients, 184 (82 TMVr, 102 GDMT) had PASP of ≥50 mm Hg (mean: 59.1 ± 8.8 mm Hg) and 344 (171 TMVr, 173 GDMT) had PASP of <50 mm Hg (mean: 36.3 ± 8.1 mm Hg). Patients with PASP of ≥50 mm Hg had higher 2-year rates of death or HF hospitalization (HFH) compared to those with PASP of <50 mm Hg (68.8% vs. 49.1%; adjusted hazard ratio: 1.52; 95% confidence interval: 1.17 to 1.97; p = 0.002). Rates of death or HFH were reduced by TMVr versus GDMT alone, irrespective of baseline PASP (pinteraction = 0.45). TMVr reduced PASP from baseline to 30 days to a greater than GDMT alone (adjusted least squares mean: -4.0 vs. -0.9 mm Hg; p = 0.006), a change that was associated with reduced risk of death or HFH between 30 days and 2 years (adjusted hazard ratio: 0.91 per -5 mm Hg PASP; 95% confidence interval: 0.86 to 0.96; p = 0.0009). CONCLUSIONS: Elevated PASP is associated with a worse prognosis in patients with HF with severe SMR. TMVr with the MitraClip reduced 30-day PASP and 2-year rates of death or HFH compared with GDMT alone, irrespective of PASP.

Auteurs: Ori Ben-Yehuda, Bahira Shahim, Shmuel Chen, Mengdan Liu, Bjorn Redfors, Rebecca T Hahn, Federico M Asch, Neil J Weissman, Diego Medvedofsky, Rishi Puri, Samir Kapadia, Anna Sannino, Paul Grayburn, Saibal Kar, Scott Lim, JoAnn Lindenfeld, William T Abraham, Michael J Mack, Gregg W Stone

---
Bron: Journal of the American College of Cardiology, https://doi.org/10.1016/j.jacc.2020.09.609. Bijgewerkt 2026-07-03T13:28:05Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.